Jim Cramer Highlights DaVita’s Massive Buybacks Yet Stays Cautious

Company Overview - DaVita Inc. (NYSE:DVA) specializes in kidney dialysis treatment through various channels including outpatient centers, hospitals, and home-based care, along with laboratory testing and physician services [2] Investment Insights - Jim Cramer highlighted DaVita's significant share buybacks over the past decade, indicating a strong commitment to returning value to shareholders [1] - Cramer is particularly interested in stocks with a favorable average annual change in share count over the last 10 years, suggesting that DaVita may be a strong candidate based on this criterion [1] Market Position - The company also offers integrated kidney care, disease management, clinical research, and transplant software solutions, positioning itself as a comprehensive provider in the kidney care sector [2]